Breaking News Instant updates and real-time market news.

ANTH

Anthera

$0.00

(0.00%)

, COOP

Mr. Cooper

$14.24

0.15 (1.06%)

08:30
01/22/19
01/22
08:30
01/22/19
08:30

Eleven option delistings on January 22nd

Option delistings effective January 22nd include Anthera Pharmaceuticals Inc (ANTH), Mr Cooper Group (COOP), Cumberland (CPIX), Advanz Pharma Corporation (CXRXF), iKang Healthcare Group Inc (ADS) (KANG), Luby's (LUB), Pengrowth Energy Corporation (PGHEF), ParkerVision Inc (PRKR), Sigma Designs Inc (SIGM), Sellas Life Sciences (SLS), and TrovaGene (TROV).

ANTH

Anthera

$0.00

(0.00%)

COOP

Mr. Cooper

$14.24

0.15 (1.06%)

CPIX

Cumberland

$5.90

(0.00%)

KANG

iKang Healthcare

$20.54

(0.00%)

LUB

Luby's

$1.55

-0.1 (-6.06%)

PRKR

ParkerVision

$0.00

(0.00%)

SIGM

Sigma Designs

$0.00

(0.00%)

SLS

Sellas Life Sciences

$1.46

-0.09 (-5.81%)

TROV

Trovagene

$0.58

0.0595 (11.36%)

  • 28

    Jan

  • 11

    Feb

ANTH Anthera
$0.00

(0.00%)

03/06/18
HCWC
03/06/18
NO CHANGE
Target $3
HCWC
Buy
Anthera risk/reward attractive into March data, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein continues to like the risk/reward equation on shares of Anthera Pharmaceuticals heading into this month's Sollpura data readout. The analyst believes the Result trial's more dose-tailoring, time, and patients allow greater room for optimization and achieving max therapeutic effect. He believes "very little positivity" is now reflected in the shares, and expects an "outsized move to the upside" should a positive result be announced later this month. Fein has a Buy rating on Anthera with a $3 price target.
03/12/18
PIPR
03/12/18
DOWNGRADE
PIPR
Underweight
Anthera downgraded to Underweight from Overweight at Piper Jaffray
03/12/18
03/12/18
DOWNGRADE
Target $0.1

Underweight
Anthera downgraded to Underweight with 10c target at Piper Jaffray
As previously reported, Piper Jaffray analyst Edward Tenthoff double downgraded Anthera to Underweight from Overweight after the company's Phase 3 trial of Sollpura missed the primary non-inferiority endpoint of Coefficient of Fat Absorption in patients with cystic fibrosis with exocrine pancreatic insufficiency, or CF-EPI. Tenthoff, who expects Anthera will further reduce headcount in order to focus on strategic alternatives, cut his price target on Anthera shares to 10c from $4 based on his value for blisibimod of $5M, less the company's net debt. In morning trading, Anthera has plunged 80% to 52c per share.
06/01/18
HCWC
06/01/18
NO CHANGE
HCWC
Buy
AzurRx hiring experienced CMO adds validation to MS1819, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju noted that AzurRx BioPharma (AZRX) hired Dr. James Pennington, who was previously Chief Medical Officer and later Senior Clinical Fellow at Anthera Pharmaceuticals (ANTH), as the company's CMO. The fact that an experience CMO such as Dr. Pennington agreed to join AzurRx adds incremental validation to MS1819, the company's candidate for EPI associated with chronic pancreatitis and cystic fibrosis, said Selvaraju, who keeps a Buy rating on AzurRx shares.
COOP Mr. Cooper
$14.24

0.15 (1.06%)

10/30/18
PIPR
10/30/18
UPGRADE
Target $15.5
PIPR
Neutral
Mr. Cooper upgraded to Neutral from Underweight at Piper Jaffray
Piper Jaffray analyst Kevin Barker upgraded Mr. Cooper to Neutral and raised his price target for the shares to $15.50 from $15. The analyst views the risk/reward as more balanced with the shares trading at 0.8 times economic tangible book value.
11/09/18
LEHM
11/09/18
UPGRADE
Target $18
LEHM
Equal Weight
Mr. Cooper upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Mark Devries upgraded Mr. Cooper to Equal Weight and raised his price target for the shares to $18 from $17. The analyst sees an improved risk/reward following the company's Q3 results and potential upside from the acquisition of Pacific Union Financial.
11/29/18
BTIG
11/29/18
INITIATION
Target $21
BTIG
Buy
Mr. Cooper initiated with a Buy at BTIG
BTIG started Mr. Cooper with a Buy rating and $21 price target.
11/30/18
BTIG
11/30/18
INITIATION
Target $21
BTIG
Buy
Mr. Cooper initiated with a Buy at BTIG
As reported earlier, BTIG analyst Giuliano Bologna initiated Mr. Cooper with a Buy rating and a price target of $21 as part of his broader research note into Mortgage Servicers. The analyst notes that the more "difficult operating environment" has created an opportunity to take advantage of dislocations in companies with more exposure to servicing, which actually do better in a rising interest rate environment. Bologna views Mr. Cooper as an attractive opportunity given its "servicing unpaid principal balance growth visibility, margin expansion potential, earnings upside from internal initiatives and upside from integrating recent acquisitions."
CPIX Cumberland
$5.90

(0.00%)

04/17/18
RILY
04/17/18
INITIATION
Target $9.25
RILY
Buy
Cumberland initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva started Cumberland Pharmaceuticals with a Buy rating and $9.25 price target. The company's base business "more than justifies" the current valuation while its pipeline offers "game-changing" potential, D'Silva tells investors in a research note.
KANG iKang Healthcare
$20.54

(0.00%)

LUB Luby's
$1.55

-0.1 (-6.06%)

PRKR ParkerVision
$0.00

(0.00%)

SIGM Sigma Designs
$0.00

(0.00%)

02/09/18
MAXM
02/09/18
UPGRADE
Target $36
MAXM
Buy
Control4 upgraded to Buy at Maxim on addressable market expansion
As reported earlier, Maxim analyst Nehal Chokshi upgraded Control4 (CTRL) to Buy from Hold and raised his price target to $36 from $33, citing expanding total addressable market and continued execution. Chokshi notes that the launch of New CA-1 controller product increases the addressable market by about 50% and gives him confidence than the company can sustain low-teen growth for a number of years. He also points to data suggesting that Silicon Labs (SLAB) buying Sigma Designs (SIGM) will not prove to be a long-term negative for Control4.
SLS Sellas Life Sciences
$1.46

-0.09 (-5.81%)

07/20/18
MAXM
07/20/18
NO CHANGE
Target $5
MAXM
Buy
Sellas Life Sciences price target lowered to $5 from $13 at Maxim
Maxim analyst Jason McCarthy lowered his price target on Sellas Life Sciences to $5 citing the impact of the company's capital raise and the resulting dilution. The analyst also kept his Buy rating, noting that the new valuation still represents "significant upside potential". With shares trading near 52-week lows and the cash runway now extended for the next round of catalysts, McCarthy says investors' focus now turns to Sellas' Galinpepimut-S program advancing toward the phase 3 study and the execution of the company's clinical programs.
07/31/18
HCWC
07/31/18
NO CHANGE
Target $4
HCWC
Buy
Sellas Life Sciences price target lowered to $4 from $11 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Sellas Life Sciences to $4 after updating his model and valuation to reflect the recent financing. The analyst keeps a Buy rating on the shares.
11/01/18
OPCO
11/01/18
INITIATION
Target $13
OPCO
Outperform
Sellas Life Sciences initiated with an Outperform at Oppenheimer
Oppenheimer analyst Hartaj Singh started Sellas Life Sciences with an Outperform rating and $13 price target. With two late-stage clinical programs nearing pivotal trials and a robust early stage pipeline, the analyst believes Sellas Life Sciences is "highly undervalued" at sub-$50M in market cap. Cancer vaccines have had a convoluted history, but Singh believes this is an area for potential investor outperformance.
11/01/18
11/01/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with a Neutral at Roth Capital. 2. T-Mobile (TMUS) initiated with a Buy at Guggenheim. 3. Kosmos (KOS) initiated with a Buy at Berenberg. 4. Sellas Life Sciences (SLS) initiated with an Outperform at Oppenheimer. 5. OFS Credit (OCCI) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
TROV Trovagene
$0.58

0.0595 (11.36%)

06/15/18
MAXM
06/15/18
UPGRADE
MAXM
Buy
Trovagene upgraded to Buy from Hold at Maxim
06/18/18
MAXM
06/18/18
UPGRADE
Target $3
MAXM
Buy
Trovagene upgraded to Buy at Maxim on positive PCM-075 news
As reported earlier Maxim analyst Jason McCarthy upgraded Trovagene to Buy from Hold with a price target of $3, citing the positive news from the company's lead drug candidate PCM-075 as well as its completion of a capital raise. The analyst notes that Trovagene's balance sheet now gives it a run rate into the second half of 2019 while the PCM-075 studies progress toward their next set of catalysts. Given the suspension of the financing overhang, McCarthy says the company's potential justifies a more constructive stance.
06/18/18
06/18/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Francesca's (FRAN) upgraded to Buy from Neutral at B. Riley FBR with analyst Susan Anderson saying she has increased confidence in the company's turnaround following meetings with management. 2. Chevron (CVX) upgraded to Outperform from Market Perform at Raymond James with analyst Pavel Molchanov saying Chevron offers relatively more leverage than most peers to higher oil prices, which should reach cyclical highs over the next 6 to 12 months, while low WTI exposure maximizes earnings and free cash flow generation. 3. Trovagene (TROV) upgraded to Buy from Hold at Maxim with analyst Jason McCarthy citing the positive news from the company's lead drug candidate PCM-075 as well as its completion of a capital raise. 4. RBS (RBS) upgraded to Buy from Hold at Investec. 5. Teva (TEVA) upgraded to Market Perform from Underperform at Wells Fargo with analyst David Maris citing a "positive meeting" with Teva's CEO Kundefinedre Schultz and CFO Mike McClellan in Israel. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/07/19
NBLE
01/07/19
INITIATION
Target $5.2
NBLE
Outperform
Trovagene initiated with an Outperform at Noble Financial
Noble Financial analyst Ahu Demir initiated Trovagene with an Outperform rating and $5.20 price target, stating that investors remain skeptical of PLK1 targeting but he foresees upside potential and likes TrovaGene's Onvansertib. He believes further data will be valuable to demonstrate anti-tumor activity and the safety profile of Onvansertib, Demir tells investors.

TODAY'S FREE FLY STORIES

IFF

International Flavors

$122.54

-0.98 (-0.79%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
International Flavors rating change at Goldman Sachs »

International Flavors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

QRVO

Qorvo

$69.15

-0.93 (-1.33%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
Qorvo rating change at Goldman Sachs »

Qorvo upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

ATI

Allegheny Technologies

$26.02

0.065 (0.25%)

21:34
03/20/19
03/20
21:34
03/20/19
21:34
Upgrade
Allegheny Technologies rating change at Goldman Sachs »

Allegheny Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INAP

Internap

$4.98

0.17 (3.53%)

21:33
03/20/19
03/20
21:33
03/20/19
21:33
Upgrade
Internap rating change at Wells Fargo »

Internap upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRI

Darden

$108.62

-1.79 (-1.62%)

, CAG

Conagra Brands

$22.91

0.095 (0.42%)

20:25
03/20/19
03/20
20:25
03/20/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

DRI

Darden

$108.62

-1.79 (-1.62%)

CAG

Conagra Brands

$22.91

0.095 (0.42%)

CMC

Commercial Metals

$16.06

-0.06 (-0.37%)

GIII

G-III Apparel

$35.09

-0.475 (-1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

HYMTF

Hyundai Motor

$0.00

(0.00%)

19:51
03/20/19
03/20
19:51
03/20/19
19:51
Periodicals
Hyundai shareholders to vote on Elliott Management dividend demand, Reuters says »

Hyundai Motor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVBF

CVB Financial

$21.12

-0.53 (-2.45%)

19:45
03/20/19
03/20
19:45
03/20/19
19:45
Hot Stocks
CVB Financial raises quarterly dividend to 18c from 14c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KAMN

Kaman

$57.84

0.345 (0.60%)

19:24
03/20/19
03/20
19:24
03/20/19
19:24
Periodicals
Kaman exploring sale of distribution segment, Bloomberg says »

Kaman is looking into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

VALE

Vale

$13.49

-0.21 (-1.53%)

19:19
03/20/19
03/20
19:19
03/20/19
19:19
Hot Stocks
Vale suspends operations at Alegria mine in Mariana complex on preventive basis »

Vale S.A. informs that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

EQH

AXA Equitable

$20.84

-0.565 (-2.64%)

19:12
03/20/19
03/20
19:12
03/20/19
19:12
Syndicate
AXA Equitable 40M share Secondary priced at $20.50 »

JPMorgan, Morgan Stanley…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

OTTW

Ottawa Bancorp

$13.56

-0.14 (-1.02%)

19:02
03/20/19
03/20
19:02
03/20/19
19:02
Hot Stocks
Ottawa Bancorp declares special dividend of 35c per share »

The special dividend will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAZZ

Jazz Pharmaceuticals

$133.73

-1.74 (-1.28%)

18:57
03/20/19
03/20
18:57
03/20/19
18:57
Hot Stocks
Jazz Pharmaceuticals' Sunosi for excessive daytime sleepiness approved by FDA »

Jazz…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

AYI

Acuity Brands

$123.00

-5.53 (-4.30%)

18:52
03/20/19
03/20
18:52
03/20/19
18:52
Upgrade
Acuity Brands rating change at Goldman Sachs »

Acuity Brands upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Apr

HYAC

Haymaker Acquisition

$11.79

(0.00%)

, OSW

OneSpaWorld

$0.00

(0.00%)

18:47
03/20/19
03/20
18:47
03/20/19
18:47
Hot Stocks
OneSpaWorld says will start trading on Nasdaq March 21 »

OneSpaWorld Holdings…

HYAC

Haymaker Acquisition

$11.79

(0.00%)

OSW

OneSpaWorld

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MLHR

Herman Miller

$35.07

-0.85 (-2.37%)

, MU

Micron

$40.08

-0.3 (-0.74%)

18:46
03/20/19
03/20
18:46
03/20/19
18:46
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

MLHR

Herman Miller

$35.07

-0.85 (-2.37%)

MU

Micron

$40.08

-0.3 (-0.74%)

WSM

Williams-Sonoma

$56.88

0.09 (0.16%)

SIEN

Sientra

$9.76

0.945 (10.73%)

EB

Eventbrite

$20.09

-0.72 (-3.46%)

GES

Guess

$22.10

-0.41 (-1.82%)

UNIT

Uniti Group

$10.01

0.15 (1.52%)

WEX

Wex

$184.85

-1.465 (-0.79%)

CBMG

Cellular Biomedicine

$18.26

0.38 (2.13%)

FTDR

Frontdoor

$32.10

-2.29 (-6.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 02

    Apr

  • 03

    Apr

  • 28

    May

  • 21

    Mar

  • 21

    Mar

SAGE

Sage Therapeutics

$152.62

-3.46 (-2.22%)

18:39
03/20/19
03/20
18:39
03/20/19
18:39
Hot Stocks
Sage Therapeutics CEO: Postpartum depression is a medical issue »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

Nvidia

$174.38

-1.39 (-0.79%)

18:27
03/20/19
03/20
18:27
03/20/19
18:27
Recommendations
Nvidia analyst commentary at Tigress Financial »

Nvidia to overcome…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CURLF

Curaleaf Holdings

$0.00

(0.00%)

, CVS

CVS Health

$56.17

-0.93 (-1.63%)

18:24
03/20/19
03/20
18:24
03/20/19
18:24
Periodicals
CVS to start selling CBD products in partnership with Curaleaf, Bloomberg says »

Curaleaf (CURLF) said…

CURLF

Curaleaf Holdings

$0.00

(0.00%)

CVS

CVS Health

$56.17

-0.93 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

PETQ

PetIQ

$29.87

0.91 (3.14%)

18:23
03/20/19
03/20
18:23
03/20/19
18:23
Hot Stocks
PetIQ CEO: We are totally transparent about our price model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

T

AT&T

$30.51

-0.19 (-0.62%)

18:21
03/20/19
03/20
18:21
03/20/19
18:21
Periodicals
AT&T CEO: Huawei makes it hard for carriers to shift suppliers, Reuters says »

AT&T CEO Randall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 24

    Apr

  • 26

    Apr

  • 07

    May

  • 20

    May

SGSOY

SGS SA

$0.00

(0.00%)

18:19
03/20/19
03/20
18:19
03/20/19
18:19
Downgrade
SGS SA rating change at Goldman Sachs »

SGS SA downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLX

Clorox

$155.94

-0.93 (-0.59%)

, RBGLY

Reckitt Benckiser

$0.00

(0.00%)

18:16
03/20/19
03/20
18:16
03/20/19
18:16
Hot Stocks
Clorox files false advertising lawsuit against Reckitt Benckiser »

The Clorox Company (CLX)…

CLX

Clorox

$155.94

-0.93 (-0.59%)

RBGLY

Reckitt Benckiser

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

BA

Boeing

$376.41

2.54 (0.68%)

18:09
03/20/19
03/20
18:09
03/20/19
18:09
Periodicals
Boeing pushes flight test to International Space Station to August, Reuters says »

Boeing has postponed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 28

    May

CE

Celanese

$101.04

0.08 (0.08%)

18:02
03/20/19
03/20
18:02
03/20/19
18:02
Hot Stocks
Celanese increases acetyl intermeditates prices »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

FTDR

Frontdoor

$32.10

-2.29 (-6.66%)

17:58
03/20/19
03/20
17:58
03/20/19
17:58
Syndicate
Frontdoor 16.73M share Secondary priced at $30.00 »

JPMorgan and Goldman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.